



Elsevier has created a [Monkeypox Information Center](#) in response to the declared public health emergency of international concern, with free information in English on the monkeypox virus. The Monkeypox Information Center is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its monkeypox related research that is available on the Monkeypox Information Center - including this research content - immediately available in publicly funded repositories, with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the Monkeypox Information Center remains active.

Detection of *monkeypox virus* with real-time PCR assays

Yu Li^{a,1}, Victoria A. Olson^{a,1}, Thomas Laue^b, Miriam T. Laker^a, Inger K. Damon^{a,*}

^a Poxvirus Program, Division of Viral and Rickettsial Diseases, National Centers of Infectious Diseases, Centers for Disease Control and Prevention, Mail Stop G-43, 1600 Clifton Road, NE, Atlanta, GA 30333, United States

^b Artus Biotech, Hamburg, Robert Koch Institut, Berlin, Germany

Received 7 September 2005; received in revised form 13 March 2006; accepted 17 March 2006

Abstract

Background: Human monkeypox, a zoonotic disease, was first reported outside of Africa during the 2003 US outbreak.

Objectives: We present two real-time PCR assays critical for laboratory diagnosis of monkeypox during the 2003 US outbreak.

Study design: A TaqMan-based assay (E9L-NVAR) targets the *orthopoxvirus* DNA polymerase gene and detects Eurasian *orthopoxviruses* other than *Variola*. A hybridization assay, utilizing a MGB Eclipse™ (Epoch Biosciences) probe, targets an envelope protein gene (B6R) and specifically detects *monkeypox virus* (MPXV). Assays were validated using coded orthopoxvirus DNA samples and used to evaluate lesion samples from five confirmed US monkeypox cases.

Results: E9L-NVAR did not detect variola (48 strains), North American orthopoxviruses (2), or DNA derived from non-poxviral rash illnesses. The assay reproducibly identified various concentrations of 13 Eurasian orthopoxvirus strains and was sensitive to 12.5 vaccinia genomes. The B6R assay recognized 15 different MPXV strains, while other orthopoxvirus (9) and bacteria (15) strains did not cross-react. Of the 13 human samples tested from confirmed cases, both assays identified 100% as containing MPXV DNA.

Conclusions: E9L-NVAR and B6R assays demonstrate 100% specificity for non-variola Eurasian orthopoxvirus and MPXV, respectively. Using two discrete viral gene targets, these assays together provide a reliable and sensitive method for quickly confirming monkeypox infections. © 2006 Elsevier B.V. All rights reserved.

Keywords: Orthopoxvirus; Monkeypox virus (MPXV); Real-time PCR; Diagnostic

1. Introduction

Orthopoxvirus monkeypox, first isolated in 1958 from captive primate rash specimens (Magnus et al., 1959), was recognized to cause human illness in 1970 during smallpox eradication campaign intensification (Jezek and Fenner, 1988; Ladnyi et al., 1972). Between 1970 and 1986, >400 monkeypox cases were reported in Africa, 95% within Zaire (now the Democratic Republic of Congo, DRC) (Jezek and Fenner, 1988). Until the 2003 US outbreak (Reed et al., 2004), no human cases had been reported outside of Africa.

Abbreviations: NVAR, non-variola; RFLP, restriction fragment length polymorphism; DRC, Democratic Republic of the Congo; Ct, threshold cycle; MGB, minor groove binding

* Corresponding author. Tel.: +1 404 639 4931; fax: +1 404 639 3111/1060.

E-mail address: iad7@cdc.gov (I.K. Damon).

¹ Authors contributed equally to this manuscript.

Human monkeypox, as described in the Congo Basin, typically presents with symptoms similar to discrete, ordinary smallpox. After about a 2-week, asymptomatic incubation period, infected individuals develop fever followed by disseminated rash. Both illnesses are transmissible between humans and can result in death. The case fatality rate for monkeypox (~0–10%) (Jezek and Fenner, 1988) is much lower than for variola major (10–30%) (Fenner et al., 1998), as is the rate of human-to-human transmissibility. Control measures for these two diseases would differ, and recent events emphasize the need for monkeypox diagnostics. After discontinuation of smallpox vaccination, susceptibility to zoonotic monkeypox increased, likely contributing to increased disease reports in DRC (Hutin et al., 2001; Meyer et al., 2002; Mwanbal et al., 1997). The US monkeypox outbreak demonstrated the ability of the virus to exploit new hosts and move globally (Reed et al., 2004).

Several nucleic acid test methods have been developed for monkeypox virus (MPXV) detection and characterization (Kulesh et al., 2004; Meyer et al., 2004). Compared with other diagnostic methods, real-time PCR has the advantages of fast, high-quantity throughput and increased sensitivity. This is the first report of real-time PCR assays used to diagnose human monkeypox from clinical rash samples. The assays target different orthopoxvirus genes: DNA polymerase (E9L) and envelope protein (B6R). We report the analytic sensitivity and specificity of both assays and demonstrate their utility for US monkeypox outbreak human rash specimens. These assays represent two sensitive, rapid diagnostic tools for identification of orthopoxviral infection within clinical samples.

2. Materials and methods

2.1. Viruses, bacteria, and clinical samples homogenization

Origins, propagation, and harvesting procedures for viral and cellular isolates are documented (Esposito and Knight, 1985; Esposito et al., 1987; Frenkel et al., 1976; Gispén et al., 1967; Hanrahan et al., 2003; Likos et al., 2005; Loparev et al., 2001; Olson et al., 2004; Pulford et al., 2004; Regnery, 1971; Ropp et al., 1995; Sarmiento et al., 1979; Seki et al., 1990) or briefly described (Table 1). Viral samples were processed as described for clinical samples. Bacteria and *Rickettsia* (Table 2) were gifts (Holmes H and Massung R, CDC). Those bacteria with potential to contaminate clinical samples (Table 3) were propagated on blood agar plates, suspended in 0.85% sterile saline (0.5 McFarland turbidity), spotted (10 μ L) onto slides, and processed to replicate conditions within a clinical sample.

Clinical samples were obtained from vesicular lesions as skin biopsies (scab or vesicle roof), vesicular fluid slide (“touch prep”), or vesicular fluid swab. Recommendations for lesion sampling can be found at <http://www.bt.cdc.gov/agent/smallpox/response-plan/files/guide-d.pdf>. In brief, samples were processed under biosafety containment conditions to form homogenates suitable for DNA extraction:

1. Skin biopsies were homogenized in sterile water or PBS (500 μ L) by freezing, disruption with a disposable pestle, and vortexing. If physical disruption was insufficient, the sample underwent further freeze–thaw/grinding cycles. Finally, samples, in closed tubes, were sonicated (cup-horn sonicator, 40% maximum output).
2. Nuclease-free water (100 μ L) was added to each spot on the slide, scraped, and recovered into a sterile tube. Water addition/scraping was repeated twice and pooled into the same tube.
3. Shafts of vesicular fluid swabs were broken near the top of the swab material. The swab was hydrated (300 μ L PBS) for 5–10 min in a sterile tube and then transferred to a Swab Extraction Tube System tube (Roche Applied Science, Indianapolis, IN). The swab/tube was spun for 1 min to rinse the swab and collect the eluent.

2.2. DNA extraction

Crude virus (viral-infected cell lysates harvested 48 hpi), semi-purified virions (Esposito et al., 1981), purified virions, scabs, bacteria, and clinical samples were homogenized (as described above), and DNA extracted using the AquaPure Genomic DNA Isolation Kit (Bio-Rad, Hercules, CA), suspended in 50 μ L AquaPure DNA hydration buffer, and stored at -20°C .

Table 1
Origin of viruses and cells used for DNA extraction for use in validation panels

Organism	Sample ID	Location	Year	Patient or supplier	Material sent to CDC
Variola	V74-227 Congo 9		1974	R. Gispén	Chicken chorioallantoic membrane
Variola	V77-1605	Somalia	1977	Female, 9 years old	Crust
Variola		Somalia	1977	Male, 23 years old	Swab, last naturally occurring case
Camelpox	V78-I-903	Somalia	1978	Female camel	Crust
Camelpox	V78-I-2379	Somalia	1978	Female camel	Crust
Monkeypox	V77-I-813	Zaire	1977	Female, 7 years old	Crust
Monkeypox	V77-I-823	Zaire	1977	Male, 1.5 years old	Crust
Monkeypox	V70-266	Sierra Leone	1970	Male, 24 years old	Crust
Monkeypox	V81-167	Zaire	1981	Male, 2 years old	Crust
Monkeypox	V81-I-179 Ivory Coast	Côte d’Ivoire	1981	Female, 3 years old	Crust
Monkeypox	V82-167	Zaire	1982	Female, 29 years old	Swab
Monkeypox	V83-036	Zaire	1983	Female, 3 years old	Swab
Monkeypox	I2003ki-DRC	DRC, formally Zaire	1998		
Vaccinia	Lister	Great Britain			
Vaccinia	Temple of Heaven	China			
Vaccinia	Wyeth/Dryvax	US			
Human-T-lymphoblast	SUP-T[VB]			ATCC #CRL-1942	
African Green Monkey	BS-C-40, clone of BS-C-1			ATCC #CCL-26	
Herpesvirus	Varicella Zoster-OKa			ATCC # VR-795	
Herpesvirus	Varicella-Webster			ATCC #VR-916	

Table 2
 E9L-NVAR assay specificity to different viral/cellular DNA^a (single assay) and sensitivity to vaccinia DNA (triplicate assays)

Organism	Sample ID	DNA	2 ng	200 pg	20 pg	2 pg	200 fg	20 fg	2 fg
<i>Eurasian orthopoxvirus</i> ^a									
Camelpox	E2379	Partially pure	21.26	24.60	29.01	34.18	ND	ND	ND
Camelpox	v78-I-903	Crude	19.92		29.67		36.48		ND
Cowpox	Brighton	Partially pure	16.05		24.85		33.11		ND
Ectromelia	Moscow	Partially pure	17.10	20.35	25.54	28.57	31.68	37.43	ND
Taterapox	Gerbilpox	Partially pure	23.56	24.66	28.60	31.00	ND	39.25	ND
Monkeypox	MPXV-ZAI-1996-016	Partially pure	15.29	19.94	22.49	27.10	30.50	35.70	ND
Monkeypox	V70-266 Sierra Leone	Partially pure	16.71		28.23		33.73		ND
Monkeypox	MPXV-ZAI-1979-005	Crude	19.21		26.66		32.19		ND
Vaccinia	Lister	Partially pure	17.48		26.34		34.55		ND
Vaccinia	Temple of Heaven	Partially pure	17.13		28.32		35.86		ND
Vaccinia	IHDW	Crude	26.19	30.43	34.21	36.04	ND	ND	ND
Vaccinia	Wyeth/Dryvax	Crude	26.69		38.19		ND		ND
Vaccinia	WYH pGS62-9-v1-1-1	Partially pure	19.33		23.60		36.71		ND
Variola	SAF65-102	Crude	ND		ND		ND		ND
Variola	SAF65-103	Crude	ND		ND		ND		ND
Variola	7124	Crude	ND		ND		ND		ND
Variola	7125	Crude	ND		ND		ND		ND
Variola	Variolator 4	Crude	ND		ND		ND		ND
Variola	Garcia	Crude	ND		ND		ND		ND
Variola	BSH	Crude	ND	ND	ND	ND	ND	ND	ND
Variola	Butler	Crude	ND	ND	ND	ND	ND	ND	ND
Variola	ETH72-17	Crude	ND		ND		ND		ND
Variola	Harper	Crude	ND		ND		ND		ND
Variola	Harvey	Crude	ND		ND		ND		ND
Variola	Heidelberg	Crude	ND		ND		ND		ND
Variola	Higgins	Crude	ND		ND		ND		ND
Variola	Hinden	Crude	ND		ND		ND		ND
Variola	Horn	Crude	ND		ND		ND		ND
Variola	Iran 2602	Crude	ND	ND	ND	ND	ND	ND	ND
Variola	Juba	Crude	ND	ND	ND	ND	ND	ND	ND
Variola	K1629	Crude	ND		ND		ND		ND
Variola	Kali Mathu	Crude	ND		ND		ND		ND
Variola	Hembula	Crude	ND		ND		ND		ND
Variola	Minnesota 124	Crude	ND		ND		ND		ND
Variola	Lee	Crude	ND		ND		ND		ND
Variola	New Dehli	Crude	ND		ND		ND		ND
Variola	Nur Islam	Crude	ND		ND		ND		ND
Variola	Lahore	Crude	ND	ND	ND	ND	ND	ND	ND
Variola	Rumbec	Crude	ND		ND		ND		ND
Variola	Shahzaman	Crude	ND		ND		ND		ND
Variola	Solaiman	Crude	ND		ND		ND		ND
Variola	Stillwell	Crude	ND		ND		ND		ND
Variola	V66-39	Crude	ND		ND		ND		ND
Variola	V68-258	Crude	ND	ND	ND	ND	ND	ND	ND
Variola	V68-59	Crude	ND		ND		ND		ND
Variola	V70-222	Crude	ND		ND		ND		ND
Variola	V70-228	Crude	ND		ND		ND		ND
Variola	Congo	Crude	ND		ND		ND		ND
Variola	V72-119	Crude	ND		ND		ND		ND
Variola	V72-143	Crude	ND	ND	ND	ND	ND	ND	ND
Variola	Nepal 73	Crude	ND		ND		ND		ND
Variola	V73-225	Crude	ND	ND	ND	ND	ND	ND	ND
Variola	v74-227 Congo 9	Crude	ND	ND	ND	ND	ND	ND	ND
Variola	V77-1252	Crude	ND	ND	ND	ND	ND	ND	ND
Variola	v77-1605	Crude	ND		ND		ND		ND
Variola	Yamada	Crude	ND		ND		ND		ND
Variola	Bombay	Crust	ND		ND		ND		ND
Variola	Hembula	Crust	ND	ND	ND	ND	ND	ND	ND
Variola	Mannan	Crust	ND	ND	ND	ND	ND	ND	ND
Variola	Kudano	Crust	ND		ND		ND		ND
Variola	Parvin	Crust	ND	ND	ND	ND	ND	ND	ND
Variola	Solaiman	Crust	ND	ND	ND	ND	ND	ND	ND

Table 2 (Continued)

Organism	Sample ID	DNA	2 ng	200 pg	20 pg	2 pg	200 fg	20 fg	2 fg
Variola	7124	Pure	ND	ND	ND	ND	ND	ND	ND
Variola	Variolator 4	Pure	ND	ND	ND	ND	ND	ND	ND
Variola	BSH	Pure	ND	ND	ND	ND	ND	ND	ND
Variola	Horn	Pure	ND		ND		ND		ND
Variola	Nepal 73	Pure	ND		ND		ND		ND
Variola	Somalia (SOM)	Pure	ND	ND	ND	ND	ND	ND	ND
Variola	V70-222	Pure	ND	ND	ND	ND	ND	ND	ND
North American <i>orthopoxviruses</i> ^a									
Raccoonpox	RCN	Partially pure	ND	ND	ND	ND	ND	ND	ND
Skunkpox	Skunkpox	Partially pure	ND		ND		ND		ND
Other rash illness or cellular DNA ^a									
Herpesvirus	HSV-1 HFEM	Pure	ND		ND		ND		ND
Herpesvirus	HSV-1 Justin	Pure	ND	ND	ND	ND	ND	ND	ND
Herpesvirus	HSV-2 patient 920	Crust	ND	ND	ND	ND	ND	ND	ND
Herpesvirus	Varicella-OKA	Pure	ND	ND	ND	ND	ND	ND	ND
Herpesvirus	Varicella-WEB	Pure	ND		ND		ND		ND
Human	Human supT	Pure	ND		ND		ND		ND
Leporipox	Myxoma	Partially pure	ND		ND		ND		ND
Monkey	BSC-40	Pure	ND		ND		ND		ND
<i>Rickettsia</i>	<i>Rickettsia akari</i>	Pure	ND	ND	ND	ND	ND	ND	ND
<i>Rickettsia</i>	<i>Rickettsia conorii</i>	Pure	ND		ND		ND		ND
	Water		ND	ND	ND	ND	ND	ND	ND
Purified <i>orthopoxvirus</i> for determination of sensitivity									
Vaccinia	Wyeth/Dryvax	Pure	16.07 ^b	19.47 ^b	23.41 ^b	27.53 ^b	31.56 ^b	35.69 ^b	39.68 ^c

^a The cycle when fluorescence crossed the threshold (Ct) for each positive sample is shown. ND, not detected.

^b Each sample was tested in triplicate, all three runs were positive, and the average Ct value is shown.

^c Each sample was tested in triplicate, one run was positive and two were negative, and the average Ct value is shown.

2.3. E9L non-variola (NVAR) assay

The primer/probe sequences were selected from the DNA polymerase gene (E9L; GenBank L22579) with Primer Express (version 1.5; Applied Biosystems). These included E9L forward primer (5'-TCA_ACT_GAA_AAG_GCC_ATC_TAT_GA-3'), E9L reverse primer (5'-GAG_TAT_AGA_GCA_CTA_TTT_CTA_AAT_CCC_A-3'), and E9L-NVAR probe (5'-TET-CCA_TGC_AAT_ATA_CGT_ACA_AGA_TAG_TAG_CCA_AC-3'). Primers and probe were synthesized in the Biotechnology Core Facility (CDC, Atlanta GA), utilizing standard phosphoramidite chemistry. The detection probe contained 5' reporter molecule (TET) and 3' aminomodifier (Glen Research, Sterling, VA). A 3' quencher molecule, QSY7 (Molecular Probes, Eugene, OR), was conjugated to the 3' amino group after synthesis.

PCR assay conditions were optimized according to standard protocols (protocol 04304449, Applied Biosystems, Foster City, CA) by adjusting primer and probe concentrations, and thermal cycling temperatures/duration. Each reaction (50 μ L) contained 1 \times TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA), 0.4 μ mol/L each primer, 200 nmol/L TaqMan probe, and 2 μ L of template DNA. Thermal cycling conditions for the ABI7700 (Applied Biosystems, Foster City, CA): one cycle of 95 $^{\circ}$ C for 10 min; followed by 40 cycles of 95 $^{\circ}$ C for 10 s, and 60 $^{\circ}$ C for 40 s. PCR amplification is based on fluorescent emission after annealing/elongation (60 $^{\circ}$ C).

2.4. B6R MPXV-specific assay

The primer sequences were selected from the extracellular enveloped virus protein gene (B6R; GenBank L22579) using Primer Express (version 1.5; Applied Biosystems, Foster City, CA). These included B6R forward primer (5'-ATT_GGT_CAT_TAT_TTT_TGT_CAC_AGG_AAC_A-3'), and B6R reverse primer (5'-AAT_GGC_GTT_GAC_AAT_TAT_GGG_TG-3'). The MPXV-specific probe (5'-MGB/DarkQuencher-AGA_GAT_TAG_AAA_TA-FAM3') was selected from the B6R sequence with the aid of MGB EclipseTM By Design software (Epoch Biosciences, Bothell, WA) and has a conjugated minor groove binding (MGB) ligand and a dark quencher at the 5'-end, with the fluorophore at the 3'-end. Fluorescence of the single-stranded probe is efficiently quenched by the interaction of the terminal dye and quencher groups when not hybridized (Afonina et al., 2002a,b).

Each reaction (20 μ L) contained 1 \times Eclipse Gene Expression Buffer (20 mmol/L Tris-HCl, pH 8.7, 50 mmol/L NaCl, 5 mmol/L MgCl₂), 200 nmol/L MGB EclipseTM probe, 0.25 μ L 100 mmol/L deoxynucleoside triphosphate mixture, 0.4 μ mol/L each primer, 0.75 μ L (1.875 U) Jumpstart TaqDNA polymerase (Sigma, St. Louis, MO), and 2 μ L template DNA. Thermal cycling conditions for the iCycler (Bio-Rad, Hercules, CA): one cycle of 95 $^{\circ}$ C for 30 s; followed by 45 cycles of 95 $^{\circ}$ C for 5 s, 57 $^{\circ}$ C for 15 s, and 70 $^{\circ}$ C for 20 s. PCR amplification is

Table 3
Validation of B6R assay specificity to Eurasian *orthopoxvirus* and bacterial DNA^a

Eurasian <i>orthopoxvirus</i>	Sample ID	DNA	Average Ct for samples with different amounts of viral DNA						
			2 ng	200 pg	20 pg	2 pg	200 fg	20 fg	2 fg
Camelpox	v78-I2379	Purified	ND	ND	ND	ND	ND	ND	ND
Cowpox	CP58	Purified	ND	ND	ND	ND	ND	ND	ND
Cowpox	Brighton	Purified	ND	ND	ND	ND	ND	ND	ND
Monkeypox	MPXV-ZAI-1979-005	Purified	17.30 ^b	21.01 ^b	26.00 ^b	29.79 ^b	33.69 ^b	36.74 ^b	39.70 ^b
Vaccinia	Wyeth/Dryvax	Purified	ND	ND	ND	ND	ND	ND	ND
Vaccinia	IHDJ	Purified	ND	ND	ND	ND	ND	ND	ND
Vaccinia	Wyeth	Purified	ND	ND	ND	ND	ND	ND	ND
Variola	V72-143	Crude	ND						
Variola	BSH	Purified	ND	ND					
Variola	Horn	Purified	ND	ND					
Bacteria ^c			Average Ct						
<i>Streptococcus Pyogenes</i> ATCC 19615			ND						
<i>Diphtheroid</i> CDC#143-02			ND						
<i>Peptostreptococcus anaerobius</i> ATCC 15689			ND						
<i>Propionibacterium acnes</i> ATCC 6919			ND						
<i>Staphylococcus aureus</i> (strain 1) ATCC 12600			ND						
<i>Klebsiella pneumoniae</i> ATCC 33495			ND						
<i>Staphylococcus epidermidis</i> (strain 3) ATCC 14990			ND						
<i>S. epidermidis</i> (strain 2) ATCC 12228			ND						
<i>S. epidermidis</i> (strain 1) ATCC 49134			ND						
<i>Pseudomonas aeruginosa</i> ATCC 27853			ND						
<i>Enterococcus faecalis</i> ATCC 29212			ND						
<i>Streptococcus bovis</i> (alpha-Strep) ATCC 49147			ND						
<i>S. aureus</i> (strain 3) CDC#03-06 (TSST-1 positive)			ND						
<i>S. aureus</i> (strain 2) ATCC 25925			ND						
<i>Escherichia coli</i> 25922			ND						

^a Each sample was tested in triplicate; all results were negative except as indicated. ND, not detected.

^b All assays were positive and the average Ct value is shown.

^c Each sample was spotted onto a slide to mimic a clinical sample (see Section 2). The slides were processed, DNA extracted, and each DNA tested in triplicate. ND, not detected.

based on the fluorescent emission with annealed probe (57 °C).

2.5. Statistical probit analysis

Analytical sensitivity was determined using purified, photometrically quantified vaccinia DNA diluted in water (24 replicates of 5 concentrations). Probit analysis as a model of non-linear regression was accomplished with commercial software (SPSS 11.0, for Mac[®] OS X; SPSS, Inc., Chicago, IL). The software determines a continuous 95% confidence interval of the probability of achieving a positive result at any given input DNA concentration within the concentration range of the experiment.

3. Results and discussion


3.1. E9L-NVAR orthopoxvirus assay

Several TaqMan-based real-time PCR assays have been developed as rapid orthopoxvirus diagnostics. One diagnostic

assay for orthopoxviral infections other than variola targets the viral DNA polymerase gene (E9L), amplifying a conserved gene segment within all Eurasian orthopoxviruses. The probe, however, targets 32 bases within the E9L gene containing a three nucleotide difference between variola and other orthopoxviruses (Fig. 1), and thus efficiently anneals to Eurasian orthopoxviruses other than variola. This orthopoxviral diagnostic can be used without raising concern that variola has been detected.

The specificity and sensitivity of the assay, designated E9L-NVAR, was determined utilizing a coded panel of multiple orthopoxviruses. Each sample was tested singly, and positive samples are denoted by the cycle where fluorescence crossed the threshold (Ct) (Table 2). E9L-NVAR identified all non-variola Eurasian orthopoxviruses (13 species) at concentrations between 2 pg and 20 fg of viral DNA, depending upon DNA quality. The assay detected 20 fg of partially purified MPXV DNA (~100 genomes). Partially purified cowpox, ectromelia, and vaccinia were identified at similar efficiencies (Table 2). Partially purified camelpox and taterapox demonstrated a diminished interaction with the E9L-NVAR probe (Table 2) due to a single base difference

E9L Non-variola (NVAR) Orthopox Generic Assay Design



B6R Monkeypox-Specific Assay Design




Fig. 1. Alignment of primers and probes with orthopoxviral DNA. The primers and probe for each of the real-time PCR assays are aligned with the targeted sequence of DNA within several orthopoxviral species. The E9L-NVAR primers and probe are completely homologous with the vaccinia Copenhagen DNA sequence. The B6R primers and probe are completely homologous with the monkeypox (CB) DNA sequence. Virus strains: monkeypox (CB) MPXV-ZAI-1996-016 (Genbank AF380138); monkeypox (US) MPXV-USA-2003-039 (Genbank DQ011154); vaccinia Copenhagen (Genbank M35027); cowpox Brighton (Genbank AF482758); ectromelia Moscow (Genbank AF012825); camelpox Kazakhstan M-96 (Genbank AF438165); taterapox (Smith GL, personal communication); variola major Bangladesh (Genbank L22579); variola minor Garcia (Genbank Y16780). CB, Congo Basin; US, United States.

between these viruses and variola in the probe target region (Fig. 1).

Vaccinia and MPXV sequences are identical in this region (Fig. 1), and serially diluted purified vaccinia DNA established linearity of the E9L-NVAR assay from 2 ng to 20 fg (83% reaction efficiency) (Table 2). Probit regression analysis determined assay sensitivity using the same preparation of purified DNA in 24 replicate amplification reactions. Amplification was positive in all 24 replicate reactions containing 20, 10, and 5 fg of vaccinia input DNA. Only 22 of 24 replicates containing 2.5 fg were detected, while no reactions containing 1.25 fg vaccinia DNA were positive (data not shown). Therefore, 2.54 fg viral DNA (~12.5 genomes) is the calculated detection limit for 95% confidence.

The E9L-NVAR assay is specific for six non-variola Eurasian orthopoxviruses, not cross-reacting with variola (48 strains) or North American orthopoxviruses (2 strains). Furthermore, E9L-NVAR assay did not cross-react with any DNA derived from rash illnesses potentially confused with orthopoxviral infection, such as herpesvirus and rickettsial infections, or with human cellular DNA (Table 2), even at high concentrations (2 ng). Overall, the E9L-NVAR assay can reproducibly detect as few as 12.5 genomes of purified vaccinia or MPXV DNA without giving false positive results.

3.2. Monkeypox-specific B6R assay

Although the E9L-NVAR assay reliably detects Eurasian orthopoxviruses, other than variola, it is unable to make a species-specific identification. Due to the low G+C content (~30%) and 90% sequence similarity to other Eurasian orthopoxviruses, it is difficult to design a monkeypox-specific TaqMan assay. To improve the reliability of a MPXV-specific assay, we utilized the MGB-based real-time PCR technology. Linking a DNA double helix MGB protein to the probe permits use of shorter probe sequences, which can detect single nucleotide polymorphisms (SNPs) (Afonina et al., 2002a,b; Belousov et al., 2004) such as within the MPXV envelope protein gene (B6R) (Fig. 1). The probe 5'-MGB molecule stabilizes probe-template interaction (Afonina et al., 2002a,b) and enhances assay specificity and sensitivity.

A coded test panel containing orthopoxviral and bacterial DNAs was assayed in triplicate using the iCycler platform (Bio-Rad, Hercules, CA) to monitor reproducibility and specificity of the B6R assay (Table 3). MPXV DNA was reproducibly detected in a linear fashion to ~10 viral copies (2 fg). The B6R assay did not cross-react with any other orthopoxviral DNA (variola, cowpox, camelpox, and vaccinia) or with 15 bacterial species. Although certain Gram-positive bacterial DNAs were less efficiently extracted, all

Table 4

Validation of B6R assay reactivity to different strains of *monkeypox virus*^a and sensitivity of the assay to purified *monkeypox virus* DNA^b

Monkeypox strain ^a	DNA	Geographic area	10 ng				
Ivory Coast V81-I-179	Crude	Cote d'Ivoire (West Africa)	16.43				
MPXV-LIB-1970-184	Purified	Liberia (West Africa)	14.30				
Utrecht	Crude	The Netherlands (original origin unknown)	22.87				
MPXV-NIG-1978	Crude	Nigeria (West Africa)	17.17				
V70-266 Sierra Leone	Crude	Sierra Leone (West Africa)	15.10				
MPXV-CAM-1990	Crude	Cameroon (Congo Basin)	20.23				
MPXV-GAB-1988-001	Crude	Gabon (Congo Basin)	22.53				
I2003ki-DRC 1998	Crude	Zaire (Congo Basin)	13.90				
MPXV-ZAI-1979-005	Crude	Zaire (Congo Basin)	15.00				
MPXV-ZAI-1996-016	Crude	Zaire (Congo Basin)	13.97				
V77-823	Crude	Zaire (Congo Basin)	14.20				
V77-813	Crude	Zaire (Congo Basin)	14.57				
V81-167	Crude	Zaire (Congo Basin)	14.33				
V82-167	Crude	Zaire (Congo Basin)	14.00				
V83-036	Crude	Zaire (Congo Basin)	14.03				
Sensitivity to purified DNA ^b							
	2 ng	200 pg	20 pg	2 pg	200 fg	20 fg	2 fg
MPXV-ZAI-1996-016 (old)	16.43	20.37	24.23	28.97	34.07	38.63	ND
MPXV-ZAI-1996-016 (fresh)	16.96	20.74	24.76	27.50	31.14	33.85	38.21

^a Ability of the assay to detect multiple strains of monkeypox virus. Each sample was tested in triplicate; all three assays were positive and the average Ct value is shown.

^b Assay limit of detection for various quantities of purified monkeypox DNA. Each sample was tested in triplicate using either freshly diluted DNA (fresh) or diluted DNA that had undergone multiple freeze–thaw cycles (old). Where all three assays were positive, the average Ct value is shown. ND, not detected.

bacterial samples mimicked conditions expected within clinical samples. Furthermore, the presence of bacterial 16S DNA was confirmed using real-time PCR (data not shown). The B6R assay should not cross-react with these potential contaminating bacteria within clinical samples. The B6R assay detects multiple monkeypox strains; all 15 isolates of MPXV DNA were detected at 10 ng (Table 4), an amount often found within rash samples. Assay linearity and sensitivity were determined using purified MPXV DNA; all quantities from 2 ng to 2 fg cross-reacted with the B6R probe in a linear fashion (Table 4). The reaction efficiency was affected by the freshness of diluted DNA and B6R assay probe and primers: freshly diluted DNA produced higher reaction efficiency (97%) than DNA that had undergone multiple freeze–thaw cycles (67%). Overall, the B6R assay demonstrates a sensitive, specific, and rapid method for identifying MPXV.

The B6R probe did not detect any of our stocks of cowpox DNA (strain BRT (Table 3) and German isolates [GER2 and GER3] (data not shown)). However, the published cowpox GRI90 sequence is unusual in that it contains more monkeypox SNPs than cowpox signatures, including within the B6R probe region. Based on available sequence information, the B6R assay would likely cross-react with cowpox GRI90, but not other diverse cowpox isolates. At this time, we are unable to obtain cowpox GRI90 DNA to experimentally assess B6R probe cross-reactivity.

3.3. Diagnostic use of real-time PCR assays during the 2003 US monkeypox outbreak

The first US human monkeypox cases were recognized in Wisconsin (Reed et al., 2004). From five of these cases, we

received a variety of rash-lesion samples at a vesicular stage of development. Samples (skin, slides, and swabs) were inoculated into tissue culture to evaluate for viral cytopathic effect and DNA extracted for various PCR-based assays. Previously established standard PCR techniques amplified the HA and ATI genes of all orthopoxviruses with subsequent Restriction Fragment Length Polymorphism RFLP analysis providing species-specific identification (Meyer et al., 1997; Ropp et al., 1995), or amplified only MPXV using monkeypox-specific primers of the E9L gene Multiplex assay (Dhar et al., 2004). Samples were assayed with both well-established assays and new real-time PCR assays (E9L-NVAR and B6R) and their performance compared.

For real-time PCR assays, a positive control (20 fg MPXV DNA) within each run established the Ct cut-off value for positivity. All monkeypox-positive samples by standard PCR or tissue culture were also detected by real-time PCR (Table 5). In fact, real-time PCR assays identified low levels of MPXV DNA, undetectable by standard PCR (Table 5, cases 2003-038 and 2003-040). Both real-time PCR assays detected viral DNA from various sample types: vesicle fluid (slides or swabs), and vesicle skin. As evidenced by different Ct values and days to evident cytopathic effect, viral DNA load varied between samples, possibly due to differences in sampling technique, disease stage, and/or sample type; vesicle skin having the highest viral amounts. MPXV-positive rash samples were collected anywhere from day 1 to day 22 after rash onset, indicating assay usefulness throughout multiple disease stages. Clinical assay specificity was demonstrated by samples (case 2003-072) which were orthopoxvirus negative by our PCR assays (Table 5), despite sample adequacy indicated by detection of human DNA (β -actin) (data not

Table 5
Analysis of clinical samples

Case number	Sample type	Lab diagnosis	Tissue culture	Standard PCR				
				HA	HA RFLP	ATI	ATI RFLP	Multiplex
Monkeypox								
2003-038 (Patient 7*)	Slide of vesicle fluid	MPX	+ (1 day)	+	MPX	+	MPX	MPX
	Skin biopsy	MPX	+ (6 days)	–	NA	–	NA	Not done
	Swab of vesicle fluid	MPX	+ (2 days)	+	Not done	+	Not done	Not done
2003-039 (Patient 4*)	Vesicle roof	MPX	+ (3 days)	+	MPX	+	MPX	MPX
	Slide of vesicle fluid	MPX	+ (3 days)	+	Inconclusive	+	MPX	Not done
	Skin biopsy	MPX	+ (3 days)	+	Inconclusive	+	MPX	Not done
	Swab of vesicle fluid	MPX	+ (3 days)	+	Inconclusive	+	MPX	Not done
	Swab of vesicle fluid	MPX	+ (6 days)	+	–	+	MPX	Not done
2003-040 (Patient 8*)	Vesicle skin	MPX	Inconclusive	+	Inconclusive	+	MPX	MPX
	Slide of vesicle skin	MPX	+ (6 days)	–	NA	–	NA	Not done
	Swab of vesicle skin	MPX	+ (6 days)	+	Inconclusive	–	NA	Not done
2003-045 (Patient 11*)	Swab of vesicle skin	MPX	+ (2 days)	+	Inconclusive	+	MPX	MPX
2003-073 (Patient 6*)	Skin biopsy	MPX	+ (1 day)	+	MPX	+	MPX	MPX
Varicella zoster virus								
2003-072	Vesicle skin	Negative	– (7 days)	–	NA	–	NA	–
	Vesicle skin	Negative	– (7 days)	–	NA	–	NA	–
Case number	Sample type	Real-time PCR		Day post rash	Day post fever			
		E9L-NVAR (Ct) ^a	B6R (Ct) ^a					
2003-038 (Patient 7*)	Slide of vesicle fluid	OPX other than variola (30)	MPX (31)	5	6			
	Skin biopsy	OPX other than variola (37)	MPX (35)	5	6			
	Swab of vesicle fluid	OPX other than variola (30)	MPX (29)	5	6			
2003-039 (Patient 4*)	Vesicle roof	OPX other than variola (15)	MPX (15)	13	10			
	Slide of vesicle fluid	OPX other than variola (24)	MPX (25)	13	10			
	Skin biopsy	OPX other than variola (24)	MPX (23)	13	10			
	Swab of vesicle fluid	OPX other than variola (20)	MPX (21)	13	10			
	Swab of vesicle fluid	OPX other than variola (24)	MPX (24)	13	10			
2003-040 (Patient 8*)	Vesicle skin	OPX other than variola (24)	MPX (24)	5	8			
	Slide of vesicle skin	OPX other than variola (38)	MPX (37)	5	8			
	Swab of vesicle skin	OPX other than variola (30)	MPX (29)	5	8			
2003-045 (Patient 11*)	Swab of vesicle skin	OPX other than variola (28)	MPX (27)	1	6			
2003-073 (Patient 6*)	Skin biopsy	OPX other than variola (15)	MPX (14)	22	NA			
2003-072	Vesicle skin	ND (40)	ND (45)	5	16			
	Vesicle skin	ND (40)	ND (45)	5	16			

Results from tissue culture, standard PCR, and real-time PCR assays are shown for each sample. MPX, monkeypox; OPX, orthopox; NA, not applicable; ND, not detected.

^a Each sample was tested in triplicate and the average Ct for each positive sample is shown. Negative samples were not detected (ND).

* Patient number found in NEJM (Reed et al., 2004).

shown), but were confirmed to contain varicella zoster virus by PCR (National Varicella Reference Laboratory, CDC, personal communication). These real-time PCR diagnostic assays proved to be highly sensitive and specific during clinical application.

4. Summary

Two rapid real-time PCR assays for the detection of orthopoxvirus and MPXV DNA have been developed. The E9L-NVAR and B6R assays target orthopoxvirus DNA poly-

merase and extracellular enveloped protein genes, respectively. These assays are highly sensitive (2 fg or ~10 viral genomes) and specific. The E9L-NVAR assay detects 13 Eurasian orthopoxviruses but not variola or North American orthopoxviruses, and the B6R assay detects MPXV isolates but no other orthopoxviruses. Neither assay gave false positives with other rash illness-causing viruses or bacteria. The E9L-NVAR assay, initially developed upon the ABI7700, has provided similar results with other real-time PCR platforms such as the Lightcycler (Roche) and iCycler (data not shown). Similarly, the B6R assay, validated on the iCycler, is compatible with the ABI7700 real-time PCR technology

(data not shown). Although validation was executed upon specific real-time PCR platforms, both assays are flexible and capable of using most available real-time PCR technologies and platforms, thereby allowing compatibility with laboratories regardless of which real-time PCR platform they possess.

During the 2003 US monkeypox outbreak, the E9L-NVAR and B6R assays provided reliable and sensitive identification of human monkeypox infections within a clinical context. Assay compatibility with multiple real-time PCR platforms allowed simultaneous testing of suspect samples for orthopoxvirus (E9L-NVAR) and MPXV (B6R) DNA. Interestingly, US MPXV isolates were distinct from previously characterized African Congo Basin isolates in both clinical manifestations and genomic sequences, more closely matching monkeypox isolates from West Africa (Likos et al., 2005; Reed et al., 2004). These relationships correlated well with the Ghanaian origin of the US monkeypox outbreak (Reed et al., 2004). The B6R assay was designed to detect Congo Basin MPXV; West African/US MPXV has one SNP within the B6R probe (Fig. 1). The lack of complete homology to the US monkeypox isolates did not adversely affect the detection of MPXV DNA within human samples (Table 5), confirming the B6R assay diagnostic utility for both known MPXV clades (Likos et al., 2005). Furthermore, monkeypox spread outside of Africa suggests these diagnostic assays may be relevant worldwide for identification of smallpox-like orthopox diseases.

Acknowledgments

The authors thank A. Michael Frace (CDC Biotechnology Core Facilities Branch) and Hermann Meyer (Institute of Microbiology of the Bundeswehr) for the B6R sequences of cowpox GER2 and GER3, Brian Holloway (CDC Biotechnology Core Facilities Branch) for helpful discussions and critical commentary on primer and probe design, members of the Sequence Facility at the Biotechnology Core Facilities Branch for sequence information critical for assay design, and Russell Regnery (Poxvirus Program, CDC) for critical commentary on the manuscript.

References

- Afonina IA, Reed MW, Lusby E, Shishkina IG, Belousov YS. Minor groove binder-conjugated DNA probes for quantitative DNA detection by hybridization-triggered fluorescence. *Biotechniques* 2002a;32:940–9.
- Afonina IA, Sanders S, Walburger DK, Belousov YS. Accurate SNP typing by real-time PCR: a comparison of minor groove binder-conjugated DNA probes. *Pharma Genomics* 2002b;48–54.
- Belousov YS, Welch RA, Sanders S, Mills A, Kulchenko A, Dempcy R, et al. Single nucleotide polymorphism genotyping by two colour melting curve analysis using the MGB Eclipse Probe System in challenging sequence environment. *Hum Genomics* 2004;1:209–17.
- Dhar AD, Werchniak AE, Li Y, Brennick JB, Goldsmith CS, Kline R, et al. Tanapox infection in a college student. *N Engl J Med* 2004;350:361–6.
- Esposito J, Brechling K, Baer G, Moss B. Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies. *Virus Genes* 1987;1:7–21.
- Esposito JJ, Cabradilla CD, Nakano JH, Obijeski JF. Intragenomic sequence transposition in monkeypox virus. *Virology* 1981;109:231–43.
- Esposito JJ, Knight JC. Orthopoxvirus DNA: a comparison of restriction profiles and maps. *Virology* 1985;143:230–51.
- Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. The epidemiology of smallpox. In: *Smallpox and its eradication*. Geneva: World Health Organization; 1998. p. 169–208.
- Frenkel N, Locker H, Batterson W, Hayward GS, Roizman B. Anatomy of herpes simplex virus DNA. VI. Defective DNA originates from the S component. *J Virol* 1976;20:527–31.
- Gispén R, Verlinde JD, Zwart P. Histopathological and virological studies on monkeypox. *Arch Gesamte Virusforsch* 1967;21:205–16.
- Hanrahan JA, Jakubowycz M, Davis BR. A smallpox false alarm. *N Engl J Med* 2003;348:467–8.
- Hutin YJ, Williams RJ, Malfait P, Pebody R, Loparev VN, Ropp SL, et al. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. *Emerg Infect Dis* 2001;7:434–8.
- Jezek Z, Fenner F. Human monkeypox. In: Melnick J, editor. *Monographs in virology*, vol. 17. Basel: Karger; 1988. p. 1–140.
- Kulesh DA, Loveless BM, Norwood D, Garrison J, Whitehouse CA, Hartmann C, et al. Monkeypox virus detection in rodents using real-time 3'-minor groove binder TaqMan assays on the Roche LightCycler. *Lab Invest* 2004;84:1200–8.
- Ladnyi ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. *Bull World Health Organ* 1972;46:593–7.
- Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, Olsen-Rasmussen M, et al. A tale of two clades: monkeypox viruses. *J Gen Virol* 2005;86:2661–72.
- Loparev VN, Massung RF, Esposito JJ, Meyer H. Detection and differentiation of old world orthopoxviruses: restriction fragment length polymorphism of the crmB gene region. *J Clin Microbiol* 2001;39:94–100.
- Magnus P, von Andersen EK, Petersen KB, Birch-Andersen A. A pox-like disease in cynomolgus monkeys. *Acta Path Microbiol Scand* 1959;46:156–76.
- Meyer H, Damon IK, Esposito JJ. Orthopoxvirus diagnostics. *Meth Mol Biol* 2004;269:119–34.
- Meyer H, Perrichot M, Stemmler M, Emmerich P, Schmitz H, Varaine F, et al. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. *J Clin Microbiol* 2002;40:2919–21.
- Meyer H, Ropp SL, Esposito JJ. Gene for A-type inclusion body protein is useful for a polymerase chain reaction assay to differentiate orthopoxviruses. *J Virol Meth* 1997;64:217–21.
- Mwanbal PT, Tshioko KF, Moudi A, Mukinda V, Mwema GN, Messinger D, et al. Human monkeypox in Kasai Oriental, Zaire (1996–1997). *Euro Surveill* 1997;2:33–5.
- Olson VA, Laue T, Laker MT, Babkin IV, Drosten C, Shchelkunov SN, et al. Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus. *J Clin Microbiol* 2004;42:1940–6.
- Pulford D, Meyer H, Brightwell G, Damon I, Kline R, Ulaeto D. Amplification refractory mutation system PCR assays for the detection of variola and orthopoxvirus. *J Virol Meth* 2004;117:81–90.
- Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, et al. The detection of monkeypox in humans in the Western Hemisphere. *N Engl J Med* 2004;350:342–50.

Regnery DC. The epidemic potential of Brazilian myxoma virus (Lausanne strain) for three species of North American cottontails. *Am J Epidemiol* 1971;94:514–9.

Ropp SL, Jin Q, Knight JC, Massung RF, Esposito JJ. PCR strategy for identification and differentiation of small pox and other orthopoxviruses. *J Clin Microbiol* 1995;33:2069–76.

Sarmiento M, Haffey M, Spear PG. Membrane proteins specified by herpes simplex viruses. III. Role of glycoprotein VP7(B2) in virion infectivity. *J Virol* 1979;29:1149–58.

Seki M, Oie M, Ichihashi Y, Shida H. Hemadsorption and fusion inhibition activities of hemagglutinin analyzed by vaccinia virus mutants. *Virology* 1990;175:372–84.